Latest From Tocagen Inc.
The firm’s stock crashed on news that its Toca 511/Toca FC regimen did not show an overall survival benefit or meet any secondary endpoints in a Phase III study in recurrent high-grade glioma.
With an average return of 33.2% in 2017, the number of biopharma IPOs that launched last year rose to 42 after falling to 30 in 2016 compared with 62 in 2015. Following a rough fourth quarter for biopharma stocks, will the IPO momentum continue in 2018?
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
- Gene Therapy, Cell Therapy
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Tocagen Inc.
- Senior Management
Martin Duvall, CEO
Mark G Foletta, EVP, CFO
Lori Kunkel, MD, Acting CMO
Nicholas A Boyle, PhD, VP, Bus. Dev. & Mktg.
Fairooz Kabbinavar, SVP, Clinical Dev.
- Contact Info
Phone: (858) 412-8400
4242 Campus Point Ct.
San Diego, CA 82121
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.